| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by NCR.
Page 2: 1 2 3 4 5 6 7
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 301 | 17 | 35 | 1553 2002 TERATOLOGY 66(3):115-121 Stromland K; Philipson E; Gronlund MA Offspring of male and female parents with thalidomide embryopathy: Birth defects and functional anomalies | 3 | 5 |
| 302 | 13 | 35 | 1666 2003 BONE MARROW TRANSPLANTATION 32(2):165-170 Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease | 1 | 2 |
| 303 | 12 | 35 | 1800 2003 MOLECULAR PHARMACOLOGY 64(2):415-420 Drucker L; Uziel O; Tohami T; Shapiro H; Radnay J; Yarkoni S; Lahav M; Lishner M Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma | 0 | 1 |
| 304 | 12 | 35 | 1854 2004 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 14(2):421-425 Perino S; Contino-Pepin C; Satchi-Fainaro R; Butterfield C; Pucci B Inhibition of angiogenesis by THAM-derived cotelomers endowed with thalidomide moieties | 0 | 0 |
| 305 | 3 | 34 | 82 1983 DEVELOPMENT GROWTH & DIFFERENTIATION 25(4):361-373 MCBRIDE WG; VARDY PH PATHOGENESIS OF THALIDOMIDE TERATOGENESIS IN THE MARMOSET (CALLITHRIX-JACCHUS) - EVIDENCE SUGGESTING A POSSIBLE TROPHIC INFLUENCE OF CHOLINERGIC NERVES IN LIMB MORPHOGENESIS | 1 | 6 |
| 306 | 2 | 34 | 300 1991 BRITISH JOURNAL OF DERMATOLOGY 125(1):62-67 BURROWS NP; WALPORT MJ; HAMMOND AH; DAVEY N; JONES RR LUPUS-ERYTHEMATOSUS PROFUNDUS WITH PARTIAL C4-DEFICIENCY RESPONDING TO THALIDOMIDE | 12 | 23 |
| 307 | 2 | 34 | 377 1993 SPECTROSCOPY LETTERS 26(4):597-619 ROTHCHILD R; SANDERS K; VENKATASUBBAN KS NMR-STUDIES OF DRUGS - USE OF LANTHANIDE SHIFT-REAGENTS IN POLAR-SOLVENT WITH THALIDOMIDE | 0 | 6 |
| 308 | 5 | 34 | 406 1994 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 16(4):717-729 SHANNON EJ; HOWE RC; MCLEAN K; HASTINGS RC THALIDOMIDE DOES NOT PERTURB CD2, CD4, CD5, CD8, HLA-DR, OR HLA-A, HLA-B, HLA-C MOLECULES IN-VITRO ON THE MEMBRANES OF CELLS WITH IMMUNE POTENTIAL | 5 | 5 |
| 309 | 13 | 34 | 447 1995 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 99(2):160-167 MCHUGH SM; RIFKIN IR; DEIGHTON J; WILSON AB; LACHMANN PJ; LOCKWOOD CM; EWAN PW THE IMMUNOSUPPRESSIVE DRUG THALIDOMIDE INDUCES T-HELPER CELL-TYPE 2 (TH2) AND CONCOMITANTLY INHIBITS TH1 CYTOKINE PRODUCTION IN MITOGEN-STIMULATED AND ANTIGEN-STIMULATED HUMAN PERIPHERAL-BLOOD MONONUCLEAR CELL-CULTURES | 108 | 145 |
| 310 | 5 | 34 | 528 1996 HEPATOLOGY 23(6):1616-1621 LopezTalavera JC; Cadelina G; Olchowski J; Merrill W; Groszmann RJ Thalidomide inhibits tumor necrosis factor alpha decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats | 7 | 52 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 311 | 12 | 34 | 801 1999 ELECTROPHORESIS 20(12):2425-2431 Meyring M; Chankvetadze B; Blaschke G Enantioseparation of thalidomide and its hydroxylated metabolites using capillary electrophoresis with various cyclodextrins and their combinations as chiral buffer additives | 2 | 13 |
| 312 | 10 | 34 | 975 2000 EUROPEAN JOURNAL OF PHARMACOLOGY 391(1-2):97-103 Ribeiro RA; Vale ML; Ferreira SH; Cunha FQ Analgesic effect of thalidomide on inflammatory pain | 3 | 18 |
| 313 | 6 | 34 | 1003 2000 JOURNAL OF CLINICAL ONCOLOGY 18(4):708-715 Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WKA Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas | 78 | 150 |
| 314 | 27 | 34 | 1297 2002 ANNALS OF PHARMACOTHERAPY 36(3):521-525 Bessmertny O; Pham T Thalidomide use in pediatric patients | 1 | 2 |
| 315 | 3 | 34 | 1439 2002 DRUG NEWS & PERSPECTIVES 15(9):604-611 Botting J The history of thalidomide | 0 | 1 |
| 316 | 16 | 34 | 1478 2002 JOURNAL OF CARDIAC FAILURE 8(5):306-314 Agoston I; Dibbs ZI; Wang F; Muller G; Zeldis JB; Mann DL; Bozkurt B Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure | 2 | 3 |
| 317 | 22 | 34 | 1554 2002 THERAPEUTIC DRUG MONITORING 24(1):104-110 Price DK; Ando Y; Kruger EA; Weiss M; Figg WD 5 '-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis | 9 | 10 |
| 318 | 5 | 34 | 1689 2003 CANCER 97(5):1234-1241 Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome | 2 | 7 |
| 319 | 7 | 34 | 1933 2004 JOURNAL OF PERIODONTOLOGY 75(1):162-168 Lima V; Vidal FDP; Rocha FAC; Brito GAC; Ribeiro RA Effects of tumor necrosis factor-alpha inhibitors pentoxifylline and thalidomide on alveolar bone loss in short-term experimental periodontal disease in rats | 0 | 0 |
| 320 | 1 | 33 | 116 1984 GEBURTSHILFE UND FRAUENHEILKUNDE 44(4):243-248 MUHLENSTEDT D; SCHWARZ M GYNECOLOGICAL AND ENDOCRINOLOGICAL INVESTIGATIONS IN WOMEN DAMAGED BY THALIDOMIDE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 321 | 1 | 33 | 183 1986 CURRENT CONTENTS (50):3-11 GARFIELD E TERATOLOGY LITERATURE AND THE THALIDOMIDE CONTROVERSY | 0 | 0 |
| 322 | 6 | 33 | 259 1989 JOURNAL OF AUTOIMMUNITY 2(2):197-202 CRAIN E; MCINTOSH KR; GORDON G; PESTRONK A; DRACHMAN DB THE EFFECT OF THALIDOMIDE ON EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS | 7 | 9 |
| 323 | 7 | 33 | 266 1990 ACTA ENDOCRINOLOGICA 123(1):79-83 LUEPRASITSAKUL W; ABEND S; ALEX S; REINHARDT W; APPEL MC; BRAVERMAN LE EFFECT OF THALIDOMIDE ON THE INCIDENCE OF IODINE-INDUCED AND SPONTANEOUS LYMPHOCYTIC THYROIDITIS AND SPONTANEOUS DIABETES-MELLITUS IN THE BB/WOR RAT | 2 | 2 |
| 324 | 1 | 33 | 346 1993 ACTA OPHTHALMOLOGICA 71(2):238-245 STROMLAND K; MILLER MT THALIDOMIDE EMBRYOPATHY - REVISITED 27 YEARS LATER | 4 | 12 |
| 325 | 17 | 33 | 359 1993 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 11(5):487-493 ATRA E; SATO EI TREATMENT OF THE CUTANEOUS LESIONS OF SYSTEMIC LUPUS-ERYTHEMATOSUS WITH THALIDOMIDE | 47 | 65 |
| 326 | 11 | 33 | 404 1994 EUROPEAN JOURNAL OF DERMATOLOGY 4(1):9-15 OCHONISKY S; REVUZ J THALIDOMIDE USE IN DERMATOLOGY | 29 | 34 |
| 327 | 6 | 33 | 540 1996 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 11(3):247-257 Klausner JD; Makonkawkeyoon S; Akarasewi P; Nakata K; Kasinrerk W; Corral L; Dewar RL; Lane HC; Freedman VH; Kaplan G The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M-tuberculosis infection | 51 | 126 |
| 328 | 22 | 33 | 549 1996 LUPUS 5(4):257-258 Stevens RJ The place of thalidomide in the treatment of inflammatory disease | 3 | 5 |
| 329 | 19 | 33 | 703 1998 IMMUNOPHARMACOLOGY 40(1):11-20 Rowland TL; McHugh SM; Deighton J; Dearman RJ; Ewan PW; Kimber I Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells | 36 | 48 |
| 330 | 12 | 33 | 714 1998 JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS 26(4):363-383 Hoglund P; Eriksson T; Bjorkman S A double-blind study of the sedative effects of the thalidomide enantiomers in humans | 11 | 15 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 331 | 10 | 33 | 716 1998 JOURNAL OF RHEUMATOLOGY 25(5):964-969 Oliver SJ; Cheng TP; Banquerigo ML; Brahn E The effect of thalidomide and 2 analogs on collagen induced arthritis | 16 | 32 |
| 332 | 15 | 33 | 741 1998 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 48(4):397-402 Zhu J; Deng GM; Diab A; Zwingenberger K; Bakhiet M; Link H Thalidomide prolongs experimental autoimmune neuritis in Lewis rats | 4 | 10 |
| 333 | 20 | 33 | 807 1999 GASTROENTEROLOGY 117(6):1271-1277 Ehrenpreis ED; Kane SV; Cohen LB; Cohen RD; Hanauer SB Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial | 44 | 132 |
| 334 | 7 | 33 | 810 1999 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 237(12):952-961 Joussen AM; Germann T; Kirchhof B Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency | 4 | 8 |
| 335 | 13 | 33 | 895 2000 BIOPHARMACEUTICS & DRUG DISPOSITION 21(1):33-40 Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women | 6 | 6 |
| 336 | 8 | 33 | 957 2000 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 119(1):123-129 La Maestra L; Zaninoni A; Marriott JB; Lazzarin A; Dalgleish AG; Barcellini W The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro | 10 | 18 |
| 337 | 12 | 33 | 961 2000 CLINICAL INFECTIOUS DISEASES 30(5):826-831 Aboulafia DM Inflammatory pseudotumor causing small bowel obstruction and mimicking lymphoma in a patient with AIDS: Clinical improvement after initiation of thalidomide treatment | 1 | 4 |
| 338 | 1 | 33 | 1089 2001 BIOMEDICAL CHROMATOGRAPHY 15(3):202-206 Duval R; Leveque H; Prigent Y; Aboul-Enein HY Enantioseparation of aminoglutethimide and thalidomide by high performance liquid chromatography or supercritical fluid chromatography on mono-2 and mono-6-O-pentenyl-beta-cyclodextrin-based chiral stationary phases | 1 | 4 |
| 339 | 17 | 33 | 1202 2001 HAEMATOLOGICA 86(4):409-413 Tosi P; Ronconi S; Zamagni E; Cellini C; Grafone T; Cangini D; Pileri SA; Baccarani M; Tura S; Cavo M Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation | 13 | 21 |
| 340 | 3 | 33 | 1314 2002 BIOORGANIC & MEDICINAL CHEMISTRY 10(9):3067-3073 Lima LM; Castro P; Machado AL; Fraga CAM; Lugnier C; de Moraes VLG; Barreiro EJ Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues | 2 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 341 | 13 | 33 | 1411 2002 CANCER 95(4):758-765 Daliani DD; Papandreou CN; Thall PF; Wang XM; Perez C; Oliva R; Pagliaro L; Amato R A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma | 6 | 11 |
| 342 | 9 | 33 | 1577 2003 ANNALS OF HEMATOLOGY 82(10):654-659 Goldschmidt H; Sonneveld P; Cremer FW; van der Holt B; Westveer P; Breitkreutz I; Benner A; Glasmacher A; Schmidt-Wolf IGD; Martin H; Hoelzer D; Ho AD; Lokhorst HM Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients | 0 | 0 |
| 343 | 10 | 33 | 1579 2003 ANNALS OF PHARMACOTHERAPY 37(4):571-576 Thompson JL; Hansen LA Thalidomide dosing in patients with relapsed or refractory multiple myelorna | 0 | 0 |
| 344 | 12 | 33 | 1717 2003 EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY 15(9):951-957 Muriel P; Fernandez-Martinez E; Perez-Alvarez V; Lara-Ochoa F; Ponce S; Garcia J; Shibayama M; Tsutsumi V Thalidomide ameliorates carbon tetrachloride induced cirrhosis in the rat | 0 | 1 |
| 345 | 10 | 33 | 1821 2003 SEMINARS IN HEMATOLOGY 40(4):17-22 Rajkumar SV Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease | 0 | 0 |
| 346 | 16 | 33 | 1837 2004 AMERICAN JOURNAL OF VETERINARY RESEARCH 65(5):659-664 Farese JR; Fox LE; Detrisac CJ; Van Gilder JA; Roberts SL; Baldwin JA Effect of thalidomide on growth and metastasis of canine osteosarcoma cells after xenotransplantation in athymic mice | 0 | 0 |
| 347 | 10 | 33 | 1881 2004 CELL BIOLOGY INTERNATIONAL 28(3):237-242 Ergun MA; Konac E; Erbas D; Ekmekci A Apoptosis and nitric oxide release induced by thalidomide, gossypol and dexamethasone in cultured human chronic myelogenous leukemic K-562 cells | 0 | 1 |
| 348 | 22 | 33 | 1888 2004 CLINICAL CANCER RESEARCH 10(17):5949-5956 Chung F; Lu J; Palmer BD; Kestell P; Browett P; Baguley BC; Tingle M; Ching LM Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients | 0 | 0 |
| 349 | 6 | 33 | 1941 2004 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2(2):327-334 Kaushal V; Kaushal GP; Melkaveri SN; Mehta P Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology | 0 | 0 |
| 350 | 0 | 32 | 27 1981 REHABILITATION 20(3):128-132 WEINWURMKRAUSE EM PARTNERSHIP AND SEXUALITY OF THALIDOMIDE-AFFECTED YOUNG-PEOPLE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 351 | 3 | 32 | 205 1987 ARCHIVES OF TOXICOLOGY 60(5):376-381 STERZ H; NOTHDURFT H; LEXA P; OCKENFELS H TERATOLOGIC STUDIES ON THE HIMALAYAN RABBIT - NEW ASPECTS OF THALIDOMIDE-INDUCED TERATOGENESIS | 6 | 10 |
| 352 | 5 | 32 | 385 1994 BIOGENIC AMINES 10(6):543-554 AUDIT CO THALIDOMIDE-INDUCED POLYAMINE ACYLATION - A NEW INSIGHT INTO THE ACYLATION MECHANISM | 3 | 3 |
| 353 | 10 | 32 | 557 1996 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 93(15):7552-7556 Turk BE; Jiang H; Liu JO Binding of thalidomide to alpha(1)-acid glyeoprotein may be involved in its inhibition of tumor necrosis factor alpha production | 40 | 50 |
| 354 | 5 | 32 | 648 1997 RESPIRATORY MEDICINE 91(1):31-39 Tavares JL; Wangoo A; Dilworth P; Marshall B; Kotecha S; Shaw RJ Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages | 24 | 39 |
| 355 | 22 | 32 | 809 1999 GASTROENTEROLOGY 117(6):1485-1488 Sands BE; Podolsky DK New life in a sleeper: Thalidomide and Crohn's disease | 8 | 25 |
| 356 | 15 | 32 | 812 1999 IMMUNOLOGY LETTERS 68(2-3):325-332 Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I Selective down-regulation of T cell-and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone | 10 | 13 |
| 357 | 6 | 32 | 832 1999 JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS 15(5):429-438 Siefert B; Pleyer U; Muller M; Hartmann C; Keipert S Influence of cyclodextrins on the in vitro corneal permeability and in vivo ocular distribution of thalidomide | 0 | 10 |
| 358 | 13 | 32 | 873 2000 AIDS RESEARCH AND HUMAN RETROVIRUSES 16(14):1345-1355 Kaplan G; Thomas S; Fierer DS; Mulligan K; Haslett PAJ; Fessel WJ; Smith LG; Kook KA; Stirling D; Schambelan M Thalidomide for the treatment of AIDS-associated wasting | 13 | 28 |
| 359 | 17 | 32 | 887 2000 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 44(9):2286-2290 Verbon A; Juffermans NP; Speelman P; van Deventer SJH; ten Berge IJM; Guchelaar HJ; van der Poll T A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans | 17 | 18 |
| 360 | 15 | 32 | 972 2000 ELECTROPHORESIS 21(15):3270-3279 Meyring M; Muhlenbrock C; Blaschke G Investigation of the stereoselective in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis | 7 | 17 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 361 | 14 | 32 | 1090 2001 BIOORGANIC & MEDICINAL CHEMISTRY 9(4):1059-1065 Gutschow M; Hecker T; Thiele A; Hauschildt S; Eger K Aza analogues of thalidomide: Synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro | 3 | 8 |
| 362 | 24 | 32 | 1149 2001 BRITISH JOURNAL OF DERMATOLOGY 144(2):310-315 Chave TA; Finlay AY; Knight AG; All-Wales Dermatology Audit Comm Thalidomide usage in Wales: the need to follow guidelines | 1 | 1 |
| 363 | 20 | 32 | 1224 2001 JOURNAL OF CLINICAL PHARMACOLOGY 41(6):662-667 Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD Thalidomide dose proportionality assessment following single doses to healthy subjects | 3 | 4 |
| 364 | 2 | 32 | 1503 2002 JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY 24(6):488-491 Soni S; Lee DS; DiVito J; Bui AH; DeRaffele G; Radel E; Kaufman HL Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide | 0 | 1 |
| 365 | 20 | 32 | 1555 2002 THERAPIE 57(6):524-529 Boulin M; Blanchet F; Isambert N; Solary E; Solier S; Collin B; Pernot C; Durnet-Archeray MJ Role of thalidomide with or without dexamethasone for refractory multiple myeloma | 0 | 0 |
| 366 | 14 | 32 | 1736 2003 INVESTIGATIONAL NEW DRUGS 21(3):359-366 Dal Lago L; Richter MF; Cancela AI; Fernandes SA; Jung KT; Rodrigues AC; Dalla Costa T; Di Leone LP; Schwartsmann G Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer | 1 | 1 |
| 367 | 19 | 32 | 1762 2003 JOURNAL OF RHEUMATOLOGY 30(12):2627-2631 Wei JCC; Chan TW; Lin HS; Huang F; Chou CT Thalidomide for severe refractory ankylosing spondylitis: A 6-month open-label trial | 0 | 1 |
| 368 | 5 | 32 | 1776 2003 LEPROSY REVIEW 74(3):288-290 Pereira GFM On thalidomide and VMO policies | 0 | 0 |
| 369 | 12 | 32 | 1780 2003 LEUKEMIA 17(4):775-779 Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer SM; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE Thalidomide as initial therapy for early-stage myeloma | 12 | 19 |
| 370 | 9 | 32 | 1910 2004 HAEMATOLOGICA 89(7):832-836 Rosinol L; Cibeira T; Blade J; Esteve J; Aymerich M; Rozman M; Segarra M; Cid MC; Filella X; Montserrat E Extramedullary multiple myeloma escapes the effect of thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 371 | 17 | 32 | 1924 2004 JOURNAL OF CLINICAL ONCOLOGY 22(16):3269-3276 Schey SA; Fields P; Bartlett JB; Clarke IA; Ashan G; Knight RD; Streetly M; Dalgleish AG Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma | 1 | 1 |
| 372 | 10 | 32 | 1962 2004 MELANOMA RESEARCH 14(1):57-62 Pawlak WZ; Legha SS Phase II study of thalidomide in patients with metastatic melanoma | 0 | 0 |
| 373 | 14 | 32 | 1975 2004 UROLOGY 63(6):1061-1065 Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma | 0 | 0 |
| 374 | 0 | 31 | 322 1992 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 230(2):140-149 STROMLAND K; MILLER MT REFRACTIVE EVALUATION IN THALIDOMIDE EMBRYOPATHY | 3 | 5 |
| 375 | 9 | 31 | 455 1995 EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 49(1-2):1-6 HARLAND CC; STEVENTON GB; MARSDEN JR THALIDOMIDE INDUCED NEUROPATHY AND GENETIC-DIFFERENCES IN DRUG-METABOLISM | 20 | 23 |
| 376 | 2 | 31 | 458 1995 FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY 12(3-4):165-174 GEIST C; WOHRMANN T; SCHNEIDER J; ZWINGENBERGER K EFFECTS OF THALIDOMIDE ON THE LOCAL SHWARTZMAN REACTION IN MICE AND RABBITS | 6 | 8 |
| 377 | 9 | 31 | 790 1999 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 118(2):315-321 Oliver SJ; Freeman SL; Corral LG; Ocampo CJ; Kaplan G Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis | 9 | 13 |
| 378 | 10 | 31 | 896 2000 BLOOD 96(9):2943-2950 Hideshima T; Chauhan D; Shima Y; Raje N; Davies FE; Tai YT; Treon SP; Lin B; Schlossman RL; Richardson P; Muller G; Stirling DI; Anderson KC Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy | 90 | 173 |
| 379 | 7 | 31 | 1162 2001 CANCER CHEMOTHERAPY AND PHARMACOLOGY 47(6):541-544 Zhou SF; Kestell P; Tingle MD; Ching LM; Paxton JW A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide | 2 | 5 |
| 380 | 5 | 31 | 1551 2002 SEMINARS IN ONCOLOGY 29(6):34-38 Durie BGM Low-dose thalidomide in myeloma: Efficacy and biologic significance | 5 | 8 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 381 | 7 | 31 | 1561 2003 ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH 27(8):2S-6S Enomoto N; Takei Y; Hirose M; Kitamura T; Ikejima K; Sato N Protective effect of thalidomide on endotoxin-induced liver injury | 0 | 1 |
| 382 | 19 | 31 | 1693 2003 CANCER RESEARCH 63(12):3189-3194 Ng SSW; Gutschow M; Weiss M; Hauschildt S; Teubert U; Hecker TK; Luzzio FA; Kruger EA; Eger K; Figg WD Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues | 4 | 6 |
| 383 | 9 | 31 | 1695 2003 CHEMICAL & PHARMACEUTICAL BULLETIN 51(9):1098-1102 Suizu M; Muroya Y; Kakuta H; Kagechika H; Tanatani A; Nagasawa K; Hashimoto Y Cyclooxygenase inhibitors derived from thalidomide | 3 | 3 |
| 384 | 3 | 31 | 1804 2003 ONCOLOGIST 8:39-45 Hussein MA Modifications to therapy for multiple myeloma: Pegylated liposomal doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide | 0 | 1 |
| 385 | 18 | 31 | 1838 2004 ANNALS OF HEMATOLOGY 83(7):467-470 Witzens M; Moehler T; Neben K; Fruehauf S; Hartschuh W; Ho AD; Goldschmidt H Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide | 0 | 0 |
| 386 | 6 | 31 | 1855 2004 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 14(16):4141-4145 Noguchi T; Sano H; Shimazawa R; Tanatani A; Miyachi H; Hashimoto Y Phenylhomophthalimide-type NOS inhibitors derived from thalidomide | 0 | 0 |
| 387 | 4 | 30 | 142 1985 BRITISH JOURNAL OF DERMATOLOGY 112(4):475-480 WULFF CH; HOYER H; ASBOEHANSEN G; BRODTHAGEN H DEVELOPMENT OF POLYNEUROPATHY DURING THALIDOMIDE THERAPY | 66 | 85 |
| 388 | 6 | 30 | 170 1985 REVUE NEUROLOGIQUE 141(11):719-728 CHAPON F; LECHEVALIER B; DASILVA DC; RIVRAIN Y; DUPUY B; DESCHAMPS P THALIDOMIDE INDUCED NEUROPATHY | 5 | 8 |
| 389 | 2 | 30 | 418 1994 MIKROCHIMICA ACTA 117(1-2):75-85 AUCELIO RQ; CAMPIGLIA AD PHARMACEUTICAL FORMULATION ANALYSIS OF THALIDOMIDE BY SOLID-SURFACE ROOM-TEMPERATURE PHOSPHORIMETRY | 1 | 10 |
| 390 | 10 | 30 | 621 1997 JOURNAL OF IMMUNOLOGY 159(10):5157-5161 Moller DR; Wysocka M; Greenlee BM; Ma XJ; Wahl L; Flockhart DA; Trinchieri G; Karp CL Inhibition of IL-12 production by thalidomide | 77 | 114 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 391 | 14 | 30 | 709 1998 JOURNAL OF IMMUNOLOGY 161(8):4236-4243 Marriott JB; Westby M; Cookson S; Guckian M; Goodbourn S; Muller G; Shire MG; Stirling D; Dalgleish AG CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production | 34 | 50 |
| 392 | 0 | 30 | 721 1998 LANCET 351(9110):1197-1199 Dally A Thalidomide: was the tragedy preventable? | 6 | 16 |
| 393 | 22 | 30 | 745 1999 AIDS RESEARCH AND HUMAN RETROVIRUSES 15(12):1047-1052 Noormohamed FH; Youle MS; Higgs CJ; Kook KA; Hawkins DA; Lant AF; Thomas SD Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects | 13 | 13 |
| 394 | 8 | 30 | 865 1999 SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 12(6):312-316 Kalofoutis A; Monastirli A; Papapanagiotou A; Georgiou S; Pasmatzi E; Sakkis T; Bolsen K; Goerz G; Merk HF; Tsambaos D Alterations of rat liver phospholipid composition induced by oral thalidomide | 0 | 0 |
| 395 | 21 | 30 | 1073 2001 ANNALS OF ONCOLOGY 12(7):885-886 Thomas DA; Kantarjian HM The revitalization of thalidomide | 4 | 5 |
| 396 | 8 | 30 | 1315 2002 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 12(7):1043-1046 Noguchi T; Shimazawa R; Nagasawa K; Hashimoto Y Thalidomide and its analogues as cyclooxygenase inhibitors | 12 | 15 |
| 397 | 19 | 30 | 1474 2002 INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE 6(7):569-572 Fu LM; Fu-Liu CS Thalidomide and tuberculosis | 2 | 3 |
| 398 | 23 | 30 | 1500 2002 JOURNAL OF LEUKOCYTE BIOLOGY 72(5):939-945 Mohty M; Stoppa AM; Blaise D; Isnardon D; Gastaut JA; Olive D; Gaugler A Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide | 2 | 6 |
| 399 | 22 | 30 | 1582 2003 ANTI-CANCER DRUGS 14(5):331-335 Dredge K; Dalgleish AG; Marriott JB Thalidomide analogs as emerging anti-cancer drugs | 3 | 8 |
| 400 | 11 | 30 | 1588 2003 ARCHIVES OF DERMATOLOGY 139(1):50-54 Housman TS; Jorizzo JL; McCarty MA; Grummer SE; Fleischer AB; Sutej PG Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus | 2 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 401 | 10 | 30 | 1880 2004 CARCINOGENESIS 25(10):1805-1812 DeCicco KL; Tanaka T; Andreola F; De Luca LM The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPAR gamma pathway | 0 | 0 |
| 402 | 15 | 30 | 1897 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 72(6):403-409 Offidani M; Corvatta L; Marconi M; Malerba L; Mele A; Olivieri A; Brunori M; Catarini M; Candela M; Capelli D; Montanari M; Rupoli S; Leoni P Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy | 0 | 0 |
| 403 | 5 | 30 | 1913 2004 INTERNATIONAL JOURNAL OF CANCER 110(2):260-265 Kedar I; Mermershtain W; Ivgi H Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy | 0 | 0 |
| 404 | 8 | 30 | 1932 2004 JOURNAL OF NEURO-ONCOLOGY 67(1-2):191-200 Baumann F; Bjeljac M; Kollias SS; Baumert BG; Brandner S; Rousson V; Yonekawa Y; Bernays RL Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme | 0 | 0 |
| 405 | 0 | 29 | 100 1983 TERATOLOGY 27(3):327-332 PARKHIE M; WEBB M EMBRYOTOXICITY AND TERATOGENICITY OF THALIDOMIDE IN RATS | 3 | 7 |
| 406 | 8 | 29 | 424 1994 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 91(9):4082-4085 DAMATO RJ; LOUGHNAN MS; FLYNN E; FOLKMAN J THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS | 333 | 732 |
| 407 | 6 | 29 | 460 1995 GENERAL PHARMACOLOGY 26(6):1243-1247 KROGER H; KLEWER M; GRATZ R; DIETRICH A; OCKENFELS H; MIESEL R EXACERBATION OF ACETAMINOPHEN HEPATOTOXICITY BY THALIDOMIDE AND PROTECTION BY NICOTINIC-ACID AMIDE | 1 | 2 |
| 408 | 6 | 29 | 642 1997 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 356(5):529-535 Dunzendorfer S; Schratzberger P; Reinisch N; Kahler CM; Wiedermann CJ Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine-and endotoxin-activated endothelium | 17 | 23 |
| 409 | 3 | 29 | 643 1997 NEUROSCIENCE LETTERS 234(2-3):123-126 Boireau A; Bordier F; Dubedat P; Peny C; Imperato A Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice | 0 | 9 |
| 410 | 2 | 29 | 815 1999 INFLAMMATION 23(6):495-505 Gallily R; Kipper-Galperin M; Brenner T Mycoplasma fermentans-induced inflammatory response of astrocytes: Selective modulation by aminoguanidine, thalidomide, pentoxifylline and IL-10 | 1 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 411 | 9 | 29 | 818 1999 INTERNATIONAL JOURNAL OF TOXICOLOGY 18(5):337-352 Teo SK; Trigg NJ; Shaw ME; Morgan JM; Thomas SD Subchronic toxicity of thalidomide in rodents after 13 weeks of oral administration | 7 | 7 |
| 412 | 7 | 29 | 1231 2001 JOURNAL OF NEURO-ONCOLOGY 54(1):31-38 Marx GM; Pavlakis N; McCowatt S; Boyle FM; Levi JA; Bell DR; Cook R; Biggs M; Little N; Wheeler HR Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme | 15 | 22 |
| 413 | 4 | 29 | 1232 2001 JOURNAL OF NEURO-ONCOLOGY 55(1):11-17 Mawrin C; Aumann V; Kirches E; Schneider-Stock R; Scherlach C; Vogel S; Mittler U; Dietzmann K; Krause G; Weis S Gliomatosis cerebri: Post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide | 0 | 4 |
| 414 | 13 | 29 | 1244 2001 MUSCLE & NERVE 24(8):1050-1057 Molloy FM; Floeter MK; Syed NA; Sandbrink F; Culcea E; Steinberg SM; Dahut W; Pluda J; Kruger EA; Reed E; Figg WD Thalidomide neuropathy in patients treated for metastatic prostate cancer | 12 | 17 |
| 415 | 16 | 29 | 1413 2002 CANCER BIOLOGY & THERAPY 1(6):669-673 Ando L; Price DK; Dahut WL; Cox MC; Reed E; Figg WD Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide | 0 | 0 |
| 416 | 14 | 29 | 1420 2002 CHEST 122(1):227-232 Baughman RP; Judson MA; Teirstein AS; Moller DR; Lower EE Thalidomide for chronic sarcoidosis | 4 | 27 |
| 417 | 7 | 29 | 1523 2002 LEUKEMIA & LYMPHOMA 43(9):1777-1782 Coleman M; Leonard J; Lyons L; Pekle K; Nahum K; Pearse R; Niesvizky R; Michaeli J BLYD (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia | 4 | 6 |
| 418 | 13 | 29 | 1534 2002 NEUROLOGY 59(12):1872-1875 Chaudhry V; Cornblath DR; Corse A; Freimer M; Simmons-O'Brien E; Vogelsang G Thalidomide-induced neuropathy | 7 | 9 |
| 419 | 2 | 29 | 1759 2003 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 31(1):19-27 Li JY; Jaworsky MS; Stirling DI The determination of a potential impurity in Thalidomide drug substance and product by HPLC with indirect UV detection | 0 | 1 |
| 420 | 7 | 29 | 1824 2003 SEMINARS IN ONCOLOGY 30(2):270-274 Coleman M; Leonard J; Lyons L; Szelenyi H; Niesvizky R Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone | 3 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 421 | 10 | 29 | 1891 2004 CYTOKINE 26(4):145-148 Rosinol L; Cibeira MT; Segarra M; Cid MC; Filella X; Aymerich M; Rozman M; Arenillas L; Esteve J; Blade J; Montserrat E Response to thalidomide in multiple myeloma: impact of angiogenic factors | 0 | 0 |
| 422 | 0 | 28 | 3 1980 INTERNATIONAL JOURNAL OF QUANTUM CHEMISTRY 18:403-409 KLASINC L; TRINAJSTIC N; KNOP JV APPLICATION OF PHOTOELECTRON-SPECTROSCOPY TO BIOLOGICALLY-ACTIVE MOLECULES AND THEIR CONSTITUENT PARTS .8. THALIDOMIDE | 0 | 0 |
| 423 | 4 | 28 | 186 1986 FOOD AND DRUG LAW JOURNAL 41(4):458-466 SHERMAN M; STRAUSS S THALIDOMIDE - A 25-YEAR PERSPECTIVE | 4 | 14 |
| 424 | 6 | 28 | 187 1986 JOURNAL OF NEUROLOGY 233(2):83-89 HESS CW; HUNZIKER T; KUPFER A; LUDIN HP THALIDOMIDE-INDUCED PERIPHERAL NEUROPATHY - A PROSPECTIVE CLINICAL, NEUROPHYSIOLOGICAL AND PHARMACOGENETIC EVALUATION | 26 | 30 |
| 425 | 4 | 28 | 441 1995 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 28(10):1069-1076 AARESTRUP FM; GONCALVESDACOSTA SC; SARNO EN THE EFFECT OF THALIDOMIDE ON BCG-INDUCED GRANULOMAS IN MICE | 2 | 9 |
| 426 | 10 | 28 | 516 1996 CHIRALITY 8(1):11-17 Reepmeyer JC Separation of R-and S-thalidomide by reversed-phase HPLC with beta-cyclodextrin in the mobile phase | 6 | 18 |
| 427 | 9 | 28 | 531 1996 IMMUNOPHARMACOLOGY 31(2-3):213-221 Geitz H; Handt S; Zwingenberger K Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade | 75 | 94 |
| 428 | 6 | 28 | 654 1997 TUBERCLE AND LUNG DISEASE 78(1):47-55 Moreira AL; Tsenova-Berkova L; Wang J; Laochumroonvorapong P; Freeman S; Freedman VH; Kaplan G Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis | 21 | 46 |
| 429 | 6 | 28 | 706 1998 INTERNATIONAL JOURNAL OF STD & AIDS 9(12):751-755 Fife K; Howard MR; Gracie F; Phillips RH; Bower M Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre | 29 | 45 |
| 430 | 8 | 28 | 726 1998 LANCET 352(9140):1586-1589 Wolkenstein P; Latarjet J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Schuhmacher MH; Milpied B; Pilorget A; Bocquet H; Brun-Buisson C; Revuz J Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis | 39 | 79 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 431 | 9 | 28 | 831 1999 JOURNAL OF NEURO-ONCOLOGY 43(2):109-114 Moreira AL; Friedlander DR; Shif B; Kaplan G; Zagzag D Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro | 22 | 37 |
| 432 | 16 | 28 | 834 1999 JOURNAL OF PHARMACEUTICAL SCIENCES 88(1):121-125 Figg WD; Raje S; Bauer KS; Tompkins A; Venzon D; Bergan R; Chen A; Hamilton M; Pluda J; Reed E Pharmacokinetics of thalidomide in an elderly prostate cancer population | 34 | 48 |
| 433 | 10 | 28 | 1023 2000 MAYO CLINIC PROCEEDINGS 75(9):897-901 Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Kyle RA; Gertz MA; Greipp PR Thalidomide in the treatment of relapsed multiple myeloma | 56 | 85 |
| 434 | 24 | 28 | 1234 2001 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 32(3):322-324 Strauss RS; Das FM Thalidomide-induced sensory neuropathy | 2 | 3 |
| 435 | 6 | 28 | 1294 2002 ANNALS OF ONCOLOGY 13(7):1029-1035 Escudier B; Lassau N; Couanet D; Angevin E; Mesrati F; Leborgne S; Garofano A; Leboulaire C; Dupouy N; Laplanche A Phase II trial of thalidomide in renal-cell carcinoma | 12 | 23 |
| 436 | 14 | 28 | 1476 2002 JAPANESE JOURNAL OF CANCER RESEARCH 93(9):1029-1036 Kakimoto T; Hattori Y; Okamoto S; Sato N; Kamata T; Yamaguchi M; Morita K; Yamada T; Takayama N; Uchida H; Shimada N; Tanigawara Y; Ikeda Y Thalidomide for the treatment of refractory multiple myeloma: Association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome | 3 | 3 |
| 437 | 6 | 28 | 1502 2002 JOURNAL OF NUCLEAR MEDICINE 43(8):1084-1089 Kinuya S; Kawashima A; Yokoyama K; Koshida K; Konishi S; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts | 1 | 7 |
| 438 | 18 | 28 | 1537 2002 ONCOLOGY-NEW YORK 16(1):22-24 Richardson P; Anderson K Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease - Drs. Paul Richardson and Kenneth Anderson respond | 0 | 0 |
| 439 | 11 | 28 | 1562 2003 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 17(5):677-682 Khan ZH; Simpson EJ; Cole AT; Holt M; MacDonald I; Pye D; Austin A; Freeman JG Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass | 0 | 1 |
| 440 | 11 | 28 | 1668 2003 BONE MARROW TRANSPLANTATION 32(6):587-592 Ghobrial IM; Dispenzieri A; Bundy KL; Gastineau DA; Rajkumar SV; Therneau TM; Lacy MQ; Witzig TE; Litzow MR; Christensen BR; Hayman S; Pribula CG; Gertz MA Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 441 | 22 | 28 | 1692 2003 CANCER RESEARCH 63(3):593-599 Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling DI; Dalgleish AG A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins | 7 | 14 |
| 442 | 2 | 28 | 1777 2003 LEPROSY REVIEW 74(3):290-294 Lockwood D; Bryceson A The return of thalidomide: new uses and renewed concerns - reply | 0 | 2 |
| 443 | 11 | 28 | 1840 2004 ANNALS OF ONCOLOGY 15(1):134-138 Zervas K; Dimopoulos MA; Hatzicharissi E; Anagnostopoulos A; Papaioannou A; Mitsouli C; Panagiotidis P; Korantzis J; Tzilianos M; Maniatis A; Greek Myeloma Study Grp Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study | 1 | 1 |
| 444 | 13 | 28 | 1879 2004 CANCER CHEMOTHERAPY AND PHARMACOLOGY 53(5):377-383 Chung F; Wang LCS; Kestell P; Baguley BC; Ching LM Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor | 2 | 2 |
| 445 | 10 | 28 | 1884 2004 CHEMICAL & PHARMACEUTICAL BULLETIN 52(8):1021-1022 Sano H; Noguchi T; Tanatani A; Miyachi H; Hashimoto Y N-phenylphthalimide-type cyclooxygenase (COX) inhibitors derived from thalidomide: Substituent effects on subtype selectivity | 0 | 0 |
| 446 | 8 | 28 | 1894 2004 DRUGS OF THE FUTURE 29(4):383-391 Hashimoto Y; Tanatani A; Nagasawa K; Miyachi H Thalidomide as a multitarget drug and its application as a template for drug design | 0 | 0 |
| 447 | 16 | 28 | 1896 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 72(1):52-57 Strupp C; Germing U; Scherer A; Kundgen A; Modder U; Gattermann N; Haas R Thalidomide for the treatment of idiopathic myelofibrosis | 0 | 0 |
| 448 | 7 | 27 | 179 1986 BRITISH JOURNAL OF DERMATOLOGY 115(3):367-370 RAMSELAAR CG; BOONE RM; KLUINNELEMANS HC THALIDOMIDE IN THE TREATMENT OF NEURO-BEHCETS SYNDROME | 10 | 20 |
| 449 | 7 | 27 | 261 1989 JOURNAL OF RHEUMATOLOGY 16(2):158-163 GUTIERREZRODRIGUEZ O; STARUSTABACAL P; GUTIERREZMONTES O TREATMENT OF REFRACTORY RHEUMATOID-ARTHRITIS - THE THALIDOMIDE EXPERIENCE | 55 | 72 |
| 450 | 0 | 27 | 269 1990 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 40-1(1):32-36 BUCH HP; OMLOR G; KNABE J STEREOSELECTIVE DIFFERENCES OF THE CNS-DEPRESSANT ACTIVITY IN A HOMOLOGOUS SERIES OF 3-ALKYL-THALIDOMIDE ANALOGS | 0 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 451 | 8 | 27 | 333 1992 LIFE SCIENCES 51(26):2107-2116 NEUBERT R; NOGUEIRA AC; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .2. CHANGES IN RECEPTORS ON BLOOD-CELLS OF A HEALTHY VOLUNTEER | 32 | 38 |
| 452 | 8 | 27 | 416 1994 LIFE SCIENCES 55(2):77-92 NOGUEIRA AC; NEUBERT R; HELGE H; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .3. SIMULTANEOUS UP-REGULATION AND DOWN-REGULATION OF DIFFERENT INTEGRIN RECEPTORS ON HUMAN WHITE BLOOD-CELLS | 56 | 63 |
| 453 | 12 | 27 | 578 1997 BIOCHEMICAL PHARMACOLOGY 53(10):1553-1557 Nicolai S; Sies H; Stahl W Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human skin fibroblasts | 6 | 11 |
| 454 | 15 | 27 | 608 1997 INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY 19(5):289-296 Pham-Huy C; Galons H; Voisin J; Zhu JR; Righenzi S; Warnet JM; Claude JR; Duc HT In vitro and in vivo immunosuppressive potential of thalidomide and its derivative, N-hydroxythalidomide, alone and in combination with cyclosporin A | 1 | 1 |
| 455 | 11 | 27 | 670 1998 BIOCHEMICAL PHARMACOLOGY 55(11):1827-1834 Bauer KS; Dixon SC; Figg WD Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent | 82 | 122 |
| 456 | 8 | 27 | 693 1998 CLINICAL PHARMACOLOGY & THERAPEUTICS 64(6):597-602 Trapnell CB; Donahue SR; Collins JM; Flockhart DA; Thacker D; Abernethy DR Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone | 13 | 15 |
| 457 | 13 | 27 | 701 1998 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 236(6):461-466 Kruse FE; Joussen AM; Rohrschneider K; Becker MD; Volcker HE Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor | 39 | 57 |
| 458 | 16 | 27 | 715 1998 JOURNAL OF PHARMACY AND PHARMACOLOGY 50(12):1409-1416 Eriksson T; Bjorkman S; Roth B; Bjork H; Hoglund P Hydroxylated metabolites of Thalidomide: Formation in-vitro and in-vivo in man | 24 | 25 |
| 459 | 8 | 27 | 794 1999 CLINICAL PHARMACOLOGY & THERAPEUTICS 65(5):483-490 Scheffler MR; Colburn W; Kook KA; Thomas SD Thalidomide does not alter estrogen-progesterone hormone single-dose pharmacokinetics | 12 | 12 |
| 460 | 12 | 27 | 821 1999 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 5(5):261-267 Scoville CD; Reading JC Open trial of thalidomide in the treatment of rheumatoid arthritis | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 461 | 18 | 27 | 992 2000 INTERNATIONAL JOURNAL OF DERMATOLOGY 39(5):383-388 Walchner M; Meurer M; Plewig G; Messer G Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus | 16 | 27 |
| 462 | 17 | 27 | 1015 2000 JOURNAL OF RHEUMATOLOGY 27(6):1429-1433 Ordi-Ros J; Cortes F; Cucurull E; Mauri M; Bujan S; Vilardell M Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy | 15 | 28 |
| 463 | 9 | 27 | 1048 2000 SEMINARS IN HEMATOLOGY 37(1):1-4 Anderson KC Thalidomide: Therapeutic potential in hematologic malignancies | 6 | 8 |
| 464 | 7 | 27 | 1200 2001 HAEMATOLOGICA 86(4):399-403 Palumbo A; Giaccone L; Bertola A; Pregno P; Bringhen S; Rus C; Triolo S; Gallo E; Pileri A; Boccadoro M Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma | 25 | 38 |
| 465 | 10 | 27 | 1221 2001 JOURNAL OF CLINICAL IMMUNOLOGY 21(5):357-364 Prehn JL; Landers C; Muller GW; Man HW; Stirling DI; Targan SR Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues | 3 | 4 |
| 466 | 8 | 27 | 1235 2001 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 298(3):1221-1226 Drenth JPH; Vonk AG; Simon A; Powell R; Van der Meer JWM Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: A randomized, double-blind, placebo-controlled trial | 1 | 7 |
| 467 | 6 | 27 | 1277 2001 SYNTHESIS-STUTTGART (7):999-1000 Seijas JA; Vazquez-Tato MP; Gonzalez-Bande C; Martinez MM; Pacios-Lopez B Microwave promoted synthesis of a rehabilitated drug: Thalidomide | 0 | 2 |
| 468 | 13 | 27 | 1286 2002 AMERICAN HEART JOURNAL 144(5):847-850 Gullestad L; Semb AG; Holt E; Skardal R; Ueland T; Yndestad A; Froland SS; Aukrust P Effect of thalidomide in patients with chronic heart failure | 1 | 4 |
| 469 | 11 | 27 | 1290 2002 AMERICAN JOURNAL OF MEDICINE 113(7):603-606 Bennett CL; Schumock GT; Desai AA; Kwaan HC; Raisch DW; Newlin R; Stadler W Thalidomide-associated deep vein thrombosis and pulmonary embolism | 3 | 6 |
| 470 | 18 | 27 | 1301 2002 ARCHIVOS DE BRONCONEUMOLOGIA 38(10):492-494 Valero FC; Gonzalez VB Lung toxicity due to thalidomide | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 471 | 12 | 27 | 1583 2003 ANTICANCER RESEARCH 23(3B):2405-2411 Fujii T; Tachibana M; Dhar DK; Ueda S; Kinugasa S; Yoshimura H; Kohno H; Nagasue N Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice | 0 | 0 |
| 472 | 5 | 27 | 1690 2003 CANCER CHEMOTHERAPY AND PHARMACOLOGY 52:S16-S23 Hashimoto Y Structural development of synthetic retinoids and thalidomide-related molecules | 0 | 0 |
| 473 | 1 | 27 | 1753 2003 JOURNAL OF MEDICAL GENETICS 40(7):473-478 Kohlhase J; Schubert L; Liebers M; Rauch A; Becker K; Mohammed SN; Newbury-Ecob R; Reardon W Mutations at the SALL4 locus on chromosome 20 result in a range of clinically overlapping phenotypes, including Okihiro syndrome, Holt-Oram syndrome, acro-renal-ocular syndrome, and patients previously reported to represent thalidomide embryopathy | 1 | 6 |
| 474 | 12 | 27 | 1794 2003 LEUKEMIA RESEARCH 27(10):909-914 Schey SA; Cavenagh J; Johnson R; Child JA; Oakervee H; Jones RW An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment | 2 | 3 |
| 475 | 14 | 27 | 1934 2004 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 310(2):571-577 Lu J; Helsby N; Palmer BD; Tingle M; Baguley BC; Kestell P; Ching LM Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans | 0 | 0 |
| 476 | 14 | 27 | 1969 2004 ONCOLOGY REPORTS 11(1):93-95 Morabito A; Fanelli M; Carillio G; Gattuso D; Sarmiento R; Gasparini G Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma | 0 | 0 |
| 477 | 15 | 26 | 268 1990 ARCHIVES OF DERMATOLOGY 126(7):923-927 REVUZ J; GUILLAUME JC; JANIER M; HANS P; MARCHAND C; SOUTEYRAND P; BONNETBLANC JM; CLAUDY A; DALLAC S; KLENE C; CRICKX B; SANCHOGARNIER H; CHAUMEIL JC CROSSOVER STUDY OF THALIDOMIDE VS PLACEBO IN SEVERE RECURRENT APHTHOUS STOMATITIS | 53 | 100 |
| 478 | 7 | 26 | 299 1990 TRANSPLANTATION 49(1):20-25 TAMURA F; VOGELSANG GB; REITZ BA; BAUMGARTNER WA; HERSKOWITZ A COMBINATION THALIDOMIDE AND CYCLOSPORINE FOR CARDIAC ALLOGRAFT-REJECTION - COMPARISON WITH COMBINATION METHYLPREDNISOLONE AND CYCLOSPORINE | 20 | 27 |
| 479 | 8 | 26 | 427 1994 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 40(5):543-548 VILANOVA M; RIBEIRO A; CARNEIRO J; ARALACHAVES M THE EFFECTS OF THALIDOMIDE TREATMENT ON AUTOIMMUNE-PRONE NZB AND MRL MICE ARE CONSISTENT WITH STIMULATION OF THE CENTRAL IMMUNE-SYSTEM .2. | 4 | 5 |
| 480 | 14 | 26 | 543 1996 JOURNAL OF MEDICINAL CHEMISTRY 39(17):3238-3240 Muller GW; Corral LG; Shire MG; Wang H; Moreira A; Kaplan G; Stirling DI Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity | 34 | 49 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 481 | 6 | 26 | 663 1998 ARCHIV DER PHARMAZIE 331(1):7-12 Teubert U; Zwingenberger K; Wnendt S; Eger K 5 '-substituted thalidomide analogs as modulators of TNF-alpha | 10 | 10 |
| 482 | 8 | 26 | 762 1999 BIOLOGICAL & PHARMACEUTICAL BULLETIN 22(2):224-226 Shimazawa R; Miyachi H; Takayama H; Kuroda K; Kato F; Kato M; Hashimoto Y Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide | 11 | 17 |
| 483 | 3 | 26 | 1179 2001 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 126(42):1183-1186 Maio G On the history of the Contergan (thalidomide) catastrophe in the light of drug legislation | 0 | 3 |
| 484 | 18 | 26 | 1222 2001 JOURNAL OF CLINICAL ONCOLOGY 19(16):3593-3595 Rajkumar SV; Kyle RA Thalidomide in the treatment of plasma cell malignancies | 6 | 7 |
| 485 | 1 | 26 | 1248 2001 NEUROTOXICOLOGY AND TERATOLOGY 23(3):255-264 Vorhees CV; Weisenburger WP; Minck DR Neurobehavioral teratogenic effects of thalidomide in rats | 1 | 3 |
| 486 | 8 | 26 | 1284 2002 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 16(12):2115-2122 Ginsburg PM; Ehrenpreis ED A pilot study of thalidomide for patients with symptomatic mesenteric panniculitis | 0 | 1 |
| 487 | 12 | 26 | 1306 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):1-3 Mathe G Thalidomide, a drug which may protect the organism against some aggressive effects of the immunologic system | 0 | 0 |
| 488 | 10 | 26 | 1435 2002 DERMATOLOGY 204(4):365-367 Nijsten T; Meuleman L; Schroyens W; Lambert J Thalidomide-induced morbilliform rash: Diagnosis and continuation of therapy, premedicated with methylprednisolone | 0 | 0 |
| 489 | 6 | 26 | 1488 2002 JOURNAL OF CLINICAL ONCOLOGY 20(11):2610-2615 Hwu WJ; Krown SE; Panageas KS; Menell JH; Chapman PB; Livingston PO; Williams LJ; Quinn CJ; Houghton AN Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial | 12 | 22 |
| 490 | 4 | 26 | 1521 2002 LEUKEMIA & LYMPHOMA 43(2):401-406 Dmoszynska A; Bojarska-Junak A; Domanski D; Rolinski J; Hus M; Soroka-Wojtaszko M Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma | 2 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 491 | 12 | 26 | 1600 2003 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 13(20):3415-3417 Man HW; Corral LG; Stirling DI; Muller GW alpha-fluoro-substituted thalidomide analogues | 1 | 1 |
| 492 | 7 | 26 | 1745 2003 JOURNAL OF CLINICAL ONCOLOGY 21(17):3351-3356 Hwu WJ; Krown SE; Menell JH; Panageas KS; Merrell J; Lamb LA; Williams LJ; Quinn CJ; Foster T; Chapman PB; Livingston PO; Wolchok JD; Houghton AN Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma | 4 | 14 |
| 493 | 10 | 26 | 1756 2003 JOURNAL OF NEURO-ONCOLOGY 64(3):193-201 Gelati M; Corsini E; Frigerio S; Pollo B; Broggi G; Croci D; Silvani A; Boiardi A; Salmaggi A Effects of thalidomide on parameters involved in angiogenesis: an in vitro study | 0 | 1 |
| 494 | 1 | 26 | 1809 2003 PEDIATRIC NEUROLOGY 29(2):151-156 Marjanovic BD; Stojanov LM; Zdravkovic DS; Kravljanac RM; Djordjevic MS Rasmussen syndrome and long-term response to thalidomide | 0 | 0 |
| 495 | 11 | 26 | 1898 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 73(2):98-103 Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure | 0 | 0 |
| 496 | 13 | 26 | 1919 2004 JOURNAL OF CHILD NEUROLOGY 19(4):250-257 Schoeman JF; Springer P; van Rensburg AJ; Swanevelder S; Hanekom WA; Haslett PAJ; Kaplan G Adjunctive thalidomide therapy for childhood tuberculous meningitis: Results of a randomized study | 0 | 0 |
| 497 | 5 | 26 | 1931 2004 JOURNAL OF NEURO-ONCOLOGY 66(3):295-299 Piribauer M; Czech T; Dieckmann K; Birner P; Hainfellner JA; Prayer D; Fazeny-Dorner B; Weinlander G; Marosi C Stabilization of a progressive hemangioblastoma under treatment with thalidomide | 0 | 0 |
| 498 | 2 | 25 | 38 1982 ARCHIVES OF DERMATOLOGICAL RESEARCH 274(3-4):363-367 MIYACHI Y; OZAKI M; UCHIDA K; NIWA Y EFFECTS OF THALIDOMIDE ON THE GENERATION OF OXYGEN INTERMEDIATES BY ZYMOSAN-STIMULATED NORMAL POLYMORPHONUCLEAR LEUKOCYTES | 14 | 22 |
| 499 | 4 | 25 | 64 1983 ARCHIVES OF DERMATOLOGY 119(10):812-815 HASPER MF CHRONIC CUTANEOUS LUPUS-ERYTHEMATOSUS - THALIDOMIDE TREATMENT OF 11 PATIENTS | 21 | 32 |
| 500 | 2 | 25 | 309 1991 JOURNAL OF EXPERIMENTAL MEDICINE 173(3):699-703 SAMPAIO EP; SARNO EN; GALILLY R; COHN ZA; KAPLAN G THALIDOMIDE SELECTIVELY INHIBITS TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION BY STIMULATED HUMAN MONOCYTES | 291 | 504 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 501 | 8 | 25 | 381 1994 ARCHIVES OF DERMATOLOGICAL RESEARCH 286(6):347-349 TSAMBAOS D; BOLSEN K; GEORGIOU S; MONASTIRLI A; GOERZ G EFFECTS OF ORAL THALIDOMIDE ON RAT-LIVER AND SKIN MICROSOMAL P450 ISOZYME ACTIVITIES AND ON URINARY PORPHYRIN EXCRETION - INTERACTION WITH ORAL HEXACHLOROBENZENE | 14 | 15 |
| 502 | 7 | 25 | 410 1994 JOURNAL OF HEPATOLOGY 21(4):496-499 MCCORMICK PA; SCOTT F; EPSTEIN O; BURROUGHS AK; SCHEUER PJ; MCINTYRE N THALIDOMIDE AS THERAPY FOR PRIMARY BILIARY-CIRRHOSIS - A DOUBLE-BLIND PLACEBO-CONTROLLED PILOT-STUDY | 6 | 11 |
| 503 | 6 | 25 | 439 1995 BLOOD 86(9):3604-3609 PARKER PM; CHAO N; NADEMANEE A; ODONNELL MR; SCHMIDT GM; SNYDER DS; STEIN AS; SMITH EP; MOLINA A; STEPAN DE; KASHYAP A; PLANAS I; SPIELBERGER R; SOMLO G; MARGOLIN K; ZWINGENBERGER K; WILSMAN K; NEGRIN RS; LONG GD; NILAND JC; BLUME KG; FORMAN SJ THALIDOMIDE AS SALVAGE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 51 | 85 |
| 504 | 4 | 25 | 442 1995 BRITISH JOURNAL OF CANCER 72(2):339-343 CHING LM; XU ZF; GUMMER BH; PALMER BD; JOSEPH WR; BAGULEY BC EFFECT OF THALIDOMIDE ON TUMOR-NECROSIS-FACTOR PRODUCTION AND ANTITUMOR-ACTIVITY INDUCED BY 5,6-DIMETHYLXANTHENONE-4-ACETIC ACID | 28 | 44 |
| 505 | 14 | 25 | 445 1995 CHIRALITY 7(1):44-52 ERIKSSON T; BJORKMAN S; ROTH B; FYGE A; HOGLUND P STEREOSPECIFIC DETERMINATION, CHIRAL INVERSION IN-VITRO AND PHARMACOKINETICS IN HUMANS OF THE ENANTIOMERS OF THALIDOMIDE | 57 | 80 |
| 506 | 8 | 25 | 463 1995 IMMUNOPHARMACOLOGY 31(1):109-116 SHANNON EJ; SANDOVAL F THALIDOMIDE INCREASES THE SYNTHESIS OF IL-2 IN CULTURES OF HUMAN MONONUCLEAR-CELLS STIMULATED WITH CONCANAVALIN-A, STAPHYLOCOCCAL-ENTEROTOXIN-A, AND PURIFIED PROTEIN DERIVATIVE | 34 | 37 |
| 507 | 3 | 25 | 500 1996 ANTICANCER RESEARCH 16(6B):3673-3677 Gutman M; Szold A; Ravid A; Lazauskas T; Merimsky O; Klausner JM Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo | 16 | 23 |
| 508 | 5 | 25 | 555 1996 NEUROREPORT 7(12):1881-1886 Kanbayashi T; Nishino S; Tafti M; Hishikawa Y; Dement WC; Mignot E Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy | 1 | 6 |
| 509 | 7 | 25 | 568 1997 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(12):1047-1054 Haslett P; Hempstead M; Seidman C; Diakun J; Vasquez D; Freedman VH; Kaplan G The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus | 36 | 57 |
| 510 | 11 | 25 | 592 1997 CLINICAL INFECTIOUS DISEASES 24(6):1223-1227 Haslett P; Tramontana J; Burroughs M; Hempstead M; Kaplan G Adverse reactions to thalidomide in patients infected with human immunodeficiency virus | 22 | 30 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 511 | 11 | 25 | 660 1998 ANNALS OF INTERNAL MEDICINE 128(6):443-+ Hamuryudan V; Mat C; Saip S; Ozyazgan Y; Siva A; Yurdakul S; Zwingenberger K; Yazici H Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome - A randomized, double-blind, placebo-controlled trial | 67 | 127 |
| 512 | 2 | 25 | 704 1998 INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 116(1):60-66 Partida-Sanchez S; Favila-Castillo L; Pedraza-Sanchez S; Gomez-Melgar M; Saul A; Estrada-Parra S; Estrada-Garcia I IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment | 9 | 13 |
| 513 | 10 | 25 | 849 1999 NATURE MEDICINE 5(5):582-585 Parman T; Wiley MJ; Wells PG Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity | 65 | 111 |
| 514 | 15 | 25 | 999 2000 JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY 14(3):140-147 Teo SK; Sabourin PJ; O'Brien K; Kook KA; Thomas SD Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients | 22 | 22 |
| 515 | 7 | 25 | 1060 2000 TETRAHEDRON LETTERS 41(37):7151-7155 Luzzio FA; Thomas EM; Figg WD Thalidomide metabolites and analogs. Part 2: Cyclic derivatives of 2-N-phthalimido-2S,3S (3-hydroxy) ornithine | 4 | 6 |
| 516 | 7 | 25 | 1172 2001 CLINICAL CANCER RESEARCH 7(11):3311-3313 Onn A; Tseng JE; Herbst RS Thalidomide, cyclooxygenase-2, and angiogenesis: Potential for therapy | 2 | 11 |
| 517 | 12 | 25 | 1216 2001 ISRAEL MEDICAL ASSOCIATION JOURNAL 3(9):644-648 Kenet G; Wardi J; Avni Y; Aeed H; Shirin H; Zaidel L; Hershkoviz R; Bruck R Amelioration of experimental colitis by thalidomide | 1 | 1 |
| 518 | 12 | 25 | 1273 2001 SEMINARS IN ONCOLOGY 28(6):593-596 Desikan RK; Jagannath S Therapeutic dilemmas with thalidomide in multiple myeloma: Case discussions | 2 | 2 |
| 519 | 5 | 25 | 1444 2002 EUROPEAN JOURNAL OF HEART FAILURE 4(4):455-460 Vescovo G; Ravara B; Angelini A; Sandri M; Carraro U; Ceconi C; Libera LD Effect of thalidomide on the skeletal muscle in experimental heart failure | 1 | 2 |
| 520 | 13 | 25 | 1492 2002 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 17(2):135-139 Bariol C; Meagher AP; Vickers CR; Byrnes DJ; Edwards PD; Hing M; Wettstein AR; Field A Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease | 8 | 13 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 521 | 2 | 25 | 1542 2002 PEDIATRIC RESEARCH 52(4):576-579 Narita N; Kato M; Tazoe M; Miyazaki K; Narita M; Okado N Increased monoamine concentration in the brain and blood of fetal thalidomide-and valproic acid-exposed rat: Putative animal models for autism | 0 | 3 |
| 522 | 5 | 25 | 1548 2002 RADIOLOGE 42(3):222-230 Scherer A; Strupp C; Wittsack HJ; Engelbrecht V; Willers R; Germing U; Gattermann N; Haas R; Modder U Dynamic contrast-enhanced MRI for the evaluation of bone marrow microcirculation in hematologic malignancies before and during thalidomide therapy | 0 | 0 |
| 523 | 13 | 25 | 1589 2003 ARCHIVES OF DERMATOLOGY 139(2):136-138 Thomas P; Walchner M; Ghoreschi K; Rocken M Successful treatment of granulomatous cheilitis with thalidomide | 0 | 0 |
| 524 | 16 | 25 | 1702 2003 CLINICAL LYMPHOMA 3(4):241-246 Seldin DC; Choufani EB; Dember LM; Wiesman JF; Berk JL; Falk RH; O'Hara C; Fennessey S; Finn KT; Wright DG; Skinner M; Sanchorawala V Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis | 5 | 9 |
| 525 | 7 | 25 | 1744 2003 JOURNAL OF CLINICAL ONCOLOGY 21(14):2732-2739 Lee CK; Barlogie B; Munshi N; Zangari M; Fassas A; Jacobson J; van Rhee F; Cottler-Fox M; Muwalla F; Tricot G DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma | 4 | 11 |
| 526 | 11 | 25 | 1754 2003 JOURNAL OF MEDICINAL CHEMISTRY 46(18):3793-3799 Luzzio FA; Mayorov AV; Ng SSW; Kruger EA; Figg WD Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNF alpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine | 1 | 1 |
| 527 | 5 | 25 | 1799 2003 MEDICAL ONCOLOGY 20(4):397-401 Fraiman G; Ganti AK; Potti A; Mehdi S Angiosarcoma of the small intestine - Possible role for thalidomide? | 0 | 0 |
| 528 | 19 | 25 | 1807 2003 ORGANIC LETTERS 5(16):2865-2867 Capitosti SM; Hansen TP; Brown ML Facile synthesis of an azido-labeled thalidomide analogue | 0 | 2 |
| 529 | 6 | 25 | 1823 2003 SEMINARS IN ONCOLOGY 30(2):265-269 Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Margaritis D; Matsouka C; Economopoulos T; Anagnostopoulos N Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone | 3 | 5 |
| 530 | 6 | 25 | 1828 2003 WORLD JOURNAL OF SURGERY 27(10):1119-1123 Mall JW; Schwenk W; Philipp AW; Buttemeyer R; Pollmann C Intraperitoneal administration of the angiogenesis inhibitor thalidomide does not impair anastomotic healing following large bowel resection in a rabbit model | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 531 | 7 | 25 | 1908 2004 HAEMATOLOGICA 89(5):552-556 Brenne AT; Romstad LH; Gimsing P; Juliusson G; Turesson I; Romundstad P; Borset M; Sundan A; Waage A Low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma | 0 | 0 |
| 532 | 17 | 25 | 1915 2004 INTERNATIONAL JOURNAL OF HEMATOLOGY 79(3):283-288 Hattori Y; Kakimoto T; Okamoto S; Sato N; Ikeda Y Thalidomide-induced severe neutropenia during treatment of multiple myeloma | 0 | 0 |
| 533 | 0 | 24 | 26 1981 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES 78(4):2545-2548 GORDON GB; SPIELBERG SP; BLAKE DA; BALASUBRAMANIAN V THALIDOMIDE TERATOGENESIS - EVIDENCE FOR A TOXIC ARENE OXIDE METABOLITE | 48 | 89 |
| 534 | 2 | 24 | 108 1984 ARTHRITIS AND RHEUMATISM 27(10):1118-1121 GUTIERREZRODRIGUEZ O THALIDOMIDE - A PROMISING NEW TREATMENT FOR RHEUMATOID-ARTHRITIS | 47 | 56 |
| 535 | 4 | 24 | 109 1984 BIOCHEMICAL PHARMACOLOGY 33(9):1471-1477 BRAUN AG; WEINREB SL TERATOGEN METABOLISM - ACTIVATION OF THALIDOMIDE AND THALIDOMIDE ANALOGS TO PRODUCTS THAT INHIBIT THE ATTACHMENT OF CELLS TO CONCANAVALIN A COATED PLASTIC SURFACES | 15 | 24 |
| 536 | 11 | 24 | 150 1985 INTERNATIONAL JOURNAL OF DERMATOLOGY 24(2):131-134 NAAFS B; FABER WR THALIDOMIDE THERAPY - AN OPEN TRIAL | 27 | 36 |
| 537 | 9 | 24 | 257 1989 DRUG METABOLISM AND DISPOSITION 17(4):402-405 CHEN TL; VOGELSANG GB; PETTY BG; BRUNDRETT RB; NOE DA; SANTOS GW; COLVIN OM PLASMA PHARMACOKINETICS AND URINARY-EXCRETION OF THALIDOMIDE AFTER ORAL DOSING IN HEALTHY MALE-VOLUNTEERS | 77 | 81 |
| 538 | 1 | 24 | 376 1993 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 90(13):5974-5978 MAKONKAWKEYOON S; LIMSONPOBRE RNR; MOREIRA AL; SCHAUF V; KAPLAN G THALIDOMIDE INHIBITS THE REPLICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 | 105 | 184 |
| 539 | 10 | 24 | 405 1994 FOLIA BIOLOGICA 40(4):161-171 BILA V; KREN V EVIDENCE FOR TERATOGENICITY OF THALIDOMIDE USING CONGENIC AND RECOMBINANT INBRED RAT STRAINS | 0 | 10 |
| 540 | 10 | 24 | 433 1995 ANNALS OF THORACIC SURGERY 59(2):277-282 UTHOFF K; ZEHR KJ; GAUDIN PB; KUMAR P; CHO PW; VOGELSANG G; HRUBAN RH; BAUMGARTNER WA; STUART RS THALIDOMIDE AS REPLACEMENT FOR STEROIDS IN IMMUNOSUPPRESSION AFTER LUNG TRANSPLANTATION | 16 | 18 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 541 | 11 | 24 | 475 1995 LIFE SCIENCES 58(4):337-348 Nogueira AC; Neubert R; Felies A; JacobMuller U; Frankus E; Neubert D Thalidomide derivatives and the immune system .6. Effects of two derivatives with no obvious teratogenic potency on the pattern of integrins and other surface receptors on blood cells of marmosets | 2 | 3 |
| 542 | 14 | 24 | 524 1996 EUROPEAN JOURNAL OF DERMATOLOGY 6(5):373-376 Charue D; Chauvin E; Duguet C; Revuz J; Bagot M Thalidomide decreases the production of GM-CSF and TNF-alpha in the mixed epidermal cell-lymphocyte reaction | 1 | 2 |
| 543 | 3 | 24 | 662 1998 ANTICANCER RESEARCH 18(6A):4409-4413 Browne WL; Wilson WR; Baguley BC; Ching LM Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid | 5 | 13 |
| 544 | 7 | 24 | 684 1998 BRITISH JOURNAL OF CANCER 78(3):336-343 Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity | 16 | 27 |
| 545 | 6 | 24 | 748 1999 AMERICAN JOURNAL OF PUBLIC HEALTH 89(1):98-101 Annas GJ; Elias S Thalidomide and the Titanic: Reconstructing the technology tragedies of the twentieth century | 5 | 7 |
| 546 | 4 | 24 | 817 1999 INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY 80(1):11-16 Arrieta O; Ortiz-Reyes A; Rembao D; Calvillo M; Rivera E; Sotelo J Protective effect of pentoxifylline plus thalidomide against septic shock in mice | 4 | 8 |
| 547 | 6 | 24 | 879 2000 AMERICAN JOURNAL OF PATHOLOGY 156(1):151-158 Sauer H; Gunther J; Hescheler J; Wartenberg M Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals | 16 | 33 |
| 548 | 12 | 24 | 1214 2001 INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 55(9):627-631 Diggle GE Thalidomide: 40 years on | 7 | 10 |
| 549 | 9 | 24 | 1282 2002 AKTUELLE NEUROLOGIE 29(3):149-152 Vogt T; Nill M; Hundsberger T Thalidomide neuropathy | 0 | 0 |
| 550 | 17 | 24 | 1428 2002 CLINICAL CANCER RESEARCH 8(11):3377-3382 Neben K; Moehler T; Benner A; Kraemer A; Egerer G; Ho AD; Goldschmidt H Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma | 9 | 13 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 551 | 16 | 24 | 1480 2002 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 767(1):145-151 Teo SK; Chandula RS; Harden JL; Stirling DI; Thomas SD Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography-tandem mass spectrometry | 4 | 5 |
| 552 | 20 | 24 | 1487 2002 JOURNAL OF CLINICAL ONCOLOGY 20(11):2607-2609 Eisen T Thalidomide in solid malignancies | 6 | 12 |
| 553 | 17 | 24 | 1499 2002 JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(5):1020-1026 Bastuji-Garin S; Ochonisky S; Bouche P; Gherardi RK; Duguet C; Djerradine Z; Poli F; Revuz J; Thalidomide Neuropathy Study Grp Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients | 9 | 12 |
| 554 | 5 | 24 | 1519 2002 LEUKEMIA & LYMPHOMA 43(1):133-137 Strupp C; Aivado M; Germing U; Gattermann N; Haas R Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: Two case reports | 1 | 4 |
| 555 | 6 | 24 | 1543 2002 PHARMACEUTICAL RESEARCH 19(1):13-19 Goosen C; Laing TJ; du Plessis J; Goosen TC; Flynn GL Physicochemical characterization and solubility analysis of thalidomide and its N-alkyl analogs | 4 | 4 |
| 556 | 14 | 24 | 1585 2003 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 47(8):2445-2449 Giamarellos-Bourboulis EJ; Poulaki H; Kostomitsopoulos N; Dontas I; Perrea D; Karayannacos PE; Giamarellou H Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide | 0 | 1 |
| 557 | 8 | 24 | 1912 2004 HISTOCHEMISTRY AND CELL BIOLOGY 122(1):27-33 Fujita K; Asami Y; Tanaka K; Akita M; Merker HJ Anti-angiogenic effects of thalidomide: expression of apoptosis-inducible active-caspase-3 in a three-dimensional collagen gel culture of aorta | 0 | 0 |
| 558 | 8 | 24 | 1920 2004 JOURNAL OF CLINICAL ONCOLOGY 22(3):424-431 Marchetti M; Barosi G; Balestri F; Viarengo G; Gentili S; Barulli S; Demory JL; Ilariucci F; Volpe A; Bordessoule D; Grossi A; Le Bousse-Kerdiles MC; Caenazzo A; Pecci A; Falcone A; Broccia G; Bendotti C; Bauduer F; Buccisano F; Dupriez B Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: A phase II trial | 0 | 0 |
| 559 | 14 | 24 | 1970 2004 ONKOLOGIE 27(2):150-154 Steurer M; Spizzo G; Mitterer M; Gastl G Low-dose thalidomide for multiple myeloma: Interim analysis of a compassionate use program | 0 | 0 |
| 560 | 10 | 23 | 253 1989 BIOMEDICINE & PHARMACOTHERAPY 43(9):693-697 MCCARTHY DM; KANFER EJ; BARRETT AJ THALIDOMIDE FOR THE THERAPY OF GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION | 15 | 17 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 561 | 7 | 23 | 306 1991 CANCER LETTERS 60(2):129-133 GERSHBEIN LL THE THALIDOMIDE ANALOG, EM-12, ENHANCES 1,2-DIMETHYLHYDRAZINE-INDUCTION OF RAT COLON ADENOCARCINOMAS | 2 | 6 |
| 562 | 1 | 23 | 365 1993 JOURNAL OF INFECTIOUS DISEASES 168(2):408-414 SAMPAIO EP; KAPLAN G; MIRANDA A; NERY JAC; MIGUEL CP; VIANA SM; SARNO EN THE INFLUENCE OF THALIDOMIDE ON THE CLINICAL AND IMMUNOLOGICAL MANIFESTATION OF ERYTHEMA-NODOSUM LEPROSUM | 141 | 212 |
| 563 | 12 | 23 | 382 1994 ARCHIVES OF DERMATOLOGY 130(1):66-69 OCHONISKY S; VERROUST J; BASTUJIGARIN S; GHERARDI R; REVUZ J THALIDOMIDE NEUROPATHY INCIDENCE AND CLINICOELECTROPHYSIOLOGIC FINDINGS IN 42 PATIENTS | 73 | 97 |
| 564 | 2 | 23 | 419 1994 NEPHRON 67(3):270-273 SILVA SRB; VIANA PCF; LUGON NV; HOETTE M; RUZANY F; LUGON JR THALIDOMIDE FOR THE TREATMENT OF UREMIC PRURITUS - A CROSSOVER RANDOMIZED DOUBLE-BLIND TRIAL | 20 | 43 |
| 565 | 7 | 23 | 438 1995 BIOLOGICAL & PHARMACEUTICAL BULLETIN 18(9):1228-1233 SASAKI K; SHIBATA Y; HASHIMOTO Y; IWASAKI S BENZYLPHTHALIMIDES AND PHENETHYLPHTHALIMIDES WITH THALIDOMIDE-LIKE ACTIVITY ON THE PRODUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA | 7 | 18 |
| 566 | 6 | 23 | 476 1995 MICROBIAL PATHOGENESIS 19(4):245-255 BURROUGHS MH; TSENOVABERKOVA L; SOKOL K; OSSIG J; TUOMANEN E; KAPLAN G EFFECT OF THALIDOMIDE ON THE INFLAMMATORY RESPONSE IN CEREBROSPINAL-FLUID IN EXPERIMENTAL BACTERIAL-MENINGITIS | 10 | 19 |
| 567 | 16 | 23 | 583 1997 BRITISH JOURNAL OF RHEUMATOLOGY 36(3):353-359 Stevens RJ; Andujar C; Edwards CJ; Ames PRJ; Barwick AR; Khamashta MA; Hughes GRV Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: Experience in sixteen consecutive patients | 36 | 49 |
| 568 | 18 | 23 | 620 1997 JOURNAL OF AOAC INTERNATIONAL 80(4):767-773 Reepmeyer JC; Cox DC Liquid chromatographic determination of thalidomide in tablets, capsules, and raw materials | 0 | 4 |
| 569 | 14 | 23 | 681 1998 BONE MARROW TRANSPLANTATION 21(6):577-581 Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasiulli A; Vassallo E; Miniero R; Uderzo C The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children | 27 | 37 |
| 570 | 10 | 23 | 688 1998 CHIRALITY 10(3):223-228 Eriksson T; Bjorkman S; Roth B; Fyge A; Hoglund P Enantiomers of thalidomide: Blood distribution and the influence of serum albumin on chiral inversion and hydrolysis | 17 | 28 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 571 | 11 | 23 | 752 1999 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 43(9):2305-2306 Ridoux O; Drancourt M Lack of in vitro antimicrosporidian activity of thalidomide | 1 | 1 |
| 572 | 9 | 23 | 799 1999 DRUG SAFETY 21(3):161-169 Lary JM; Daniel KL; Erickson JD; Roberts HE; Moore CA The return of thalidomide - Can birth defects be prevented? | 5 | 10 |
| 573 | 12 | 23 | 833 1999 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 28(2):214-216 Weinstein TA; Sciubba JJ; Levine J Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease | 10 | 21 |
| 574 | 6 | 23 | 836 1999 JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN 57(2):92-104 Shimazawa R; Takayama H; Hashimoto Y Development of novel biological response modifiers derived from thalidomide | 0 | 7 |
| 575 | 7 | 23 | 969 2000 DIABETES CARE 23(8):1172-1176 Iqbal N; Zayed M; Boden G Thalidomide impairs insulin action on glucose uptake and glycogen synthesis in patients with type 2 diabetes | 3 | 3 |
| 576 | 2 | 23 | 1085 2001 BIOCHEMICAL PHARMACOLOGY 62(8):1081-1086 Onat D; Stahl W; Sies H Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human fetal skin fibroblasts (HFFF2) and in rat liver epithelial cells (WB-F344) | 2 | 3 |
| 577 | 13 | 23 | 1213 2001 INTERNATIONAL IMMUNOPHARMACOLOGY 1(1):49-61 Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B | 5 | 8 |
| 578 | 9 | 23 | 1230 2001 JOURNAL OF NEURO-ONCOLOGY 51(1):41-45 Short SC; Traish D; Dowe A; Hines F; Gore M; Brada M Thalidomide as an anti-angiogenic agent in relapsed gliomas | 12 | 22 |
| 579 | 4 | 23 | 1322 2002 BLOOD 100(4):1168-1171 Zangari M; Siegel E; Barlogie B; Anaissie E; Saghafifar F; Fassas A; Morris C; Fink L; Tricot G Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy | 19 | 33 |
| 580 | 10 | 23 | 1414 2002 CANCER CHEMOTHERAPY AND PHARMACOLOGY 50(3):186-192 Ding Q; Kestell P; Baguley BC; Palmer BD; Paxton JW; Muller G; Ching LM Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide | 2 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 581 | 8 | 23 | 1446 2002 EUROPEAN JOURNAL OF SURGERY 168(11):641-645 Mall JW; Schwenk W; Philipp AW; Muller JM; Pollmann C Thalidomide given intraperitoneally reduces the number of postoperative adhesions after large bowel resection in rabbits | 0 | 0 |
| 582 | 18 | 23 | 1459 2002 HAEMATOLOGICA 87(3):233-234 Tosi P; Cavo M Thalidomide in multiple myeloma: state of art | 3 | 4 |
| 583 | 5 | 23 | 1522 2002 LEUKEMIA & LYMPHOMA 43(6):1267-1271 Badros A; Morris C; Zangari M; Barlogie B; Tricot G Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia | 3 | 3 |
| 584 | 9 | 23 | 1531 2002 MEDICAL ONCOLOGY 19(4):219-226 Srkalovic G; Elson P; Trebisky B; Karam MA; Hussein MA Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma | 1 | 2 |
| 585 | 13 | 23 | 1735 2003 INTERNATIONAL JOURNAL OF ONCOLOGY 23(6):1651-1655 Kaicker S; McCrudden KW; Beck L; New T; Huang JZ; Frischer JS; Serur A; Kadenhe-Chiweshe A; Yokoi A; Kandel JJ; Yamashiro DJ Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma | 0 | 0 |
| 586 | 13 | 23 | 1761 2003 JOURNAL OF PHARMACY AND PHARMACOLOGY 55(12):1701-1706 Eriksson T; Hoglund P; Turesson I; Waage A; Don BR; Vu J; Scheffler M; Kaysen GA Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis | 3 | 3 |
| 587 | 14 | 23 | 1820 2003 SEMINARS IN HEMATOLOGY 40(4):8-16 Dimopoulos MA; Anagnostopoulos A Thalidomide in relapsed/refractory multiple myeloma: Pivotal trials conducted outside the United States | 0 | 0 |
| 588 | 12 | 23 | 1829 2003 XENOTRANSPLANTATION 10(5):470-474 Yamamoto S; Cooper DKC An investigation of the effect of thalidomide on anti-gal antibody production in baboons | 0 | 0 |
| 589 | 11 | 23 | 1844 2004 ANNALS OF PHARMACOTHERAPY 38(5):808-811 Sayarlioglu M; Kotan MC; Topcu N; Bayram I; Arslanturk H; Gul A Treatment of recurrent perforating intestinal ulcers with thalidomide in Behcet's disease | 0 | 0 |
| 590 | 6 | 23 | 1883 2004 CHEMICAL & PHARMACEUTICAL BULLETIN 52(4):498-499 Shimazawa R; Sano H; Tanatani A; Miyachi H; Hashimoto Y Thalidomide as a nitric oxide synthase inhibitor and its structural development | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 591 | 3 | 23 | 1889 2004 CLINICAL NEPHROLOGY 61(5):352-356 Menegato MA; Canelles MF; Tonutti E; Pizzolitto S Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease | 0 | 0 |
| 592 | 14 | 23 | 1917 2004 INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 60(2):353-357 Chang SM; Lamborn KR; Malec M; Larson D; Wara W; Sneed P; Rabbitt J; Page M; Nicholas MK; Prados MD Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme | 0 | 0 |
| 593 | 14 | 23 | 1930 2004 JOURNAL OF MEDICINAL CHEMISTRY 47(9):2219-2227 Lepper ER; Ng SSW; Gutschow M; Weiss M; Hauschildt S; Hecker TK; Luzzio FA; Eger K; Figg WD Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors | 0 | 0 |
| 594 | 13 | 23 | 1937 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 51(1):126-131 Sansbury JC; Cocuroccia B; Jorizzo JL; Gubinelli E; Gisondi P; Girolomoni G Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients | 0 | 0 |
| 595 | 0 | 22 | 41 1982 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 32-1(6):613-620 FRIDERICHS E STUDIES ON THE CNS ACTIVITY PROFILE OF THALIDOMIDE ANALOGS | 0 | 8 |
| 596 | 7 | 22 | 380 1994 ANNALS OF THE RHEUMATIC DISEASES 53(12):828-832 GARDNERMEDWIN JMM; SMITH NJ; POWELL RJ CLINICAL-EXPERIENCE WITH THALIDOMIDE IN THE MANAGEMENT OF SEVERE ORAL AND GENITAL ULCERATION IN CONDITIONS SUCH AS BEHCETS-DISEASE - USE OF NEUROPHYSIOLOGICAL STUDIES TO DETECT THALIDOMIDE NEUROPATHY | 53 | 73 |
| 597 | 14 | 22 | 402 1994 DERMATOLOGY 189(2):179-181 BIELSA I; TEIXIDO J; RIBERA M; FERRANDIZ C ERYTHRODERMA DUE TO THALIDOMIDE - REPORT OF 2 CASES | 13 | 17 |
| 598 | 4 | 22 | 434 1995 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 39(12):2807-2809 PETERSON PK; GEKKER G; BORNEMANN M; CHATTERJEE D; CHAO CC THALIDOMIDE INHIBITS LIPOARABINOMANNAN-INDUCED UP-REGULATION OF HUMAN-IMMUNODEFICIENCY-VIRUS EXPRESSION | 3 | 10 |
| 599 | 8 | 22 | 504 1996 ARCHIVES OF TOXICOLOGY 70(11):749-756 Schmahl HJ; Dencker L; Plum C; Chahoud I; Nau H Stereoselective distribution of the teratogenic thalidomide analogue EM12 in the early embryo of marmoset monkey, Wistar rat and NMRI mouse | 3 | 7 |
| 600 | 13 | 22 | 517 1996 CHIRALITY 8(5):390-396 Wnendt S; Finkam M; Winter W; Ossig J; Raabe G; Zwingenberger K Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues | 28 | 34 |